Study of Dutogliptin in Combination With Filgrastim in Post-Myocardial Infarction

Acute Myocardial Infarction Clinical Trial

Official title:

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Dutogliptin in Combination With Filgrastim in Early Recovery Post-Myocardial Infarction

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03486080
• Other study ID #: REC-DUT-002
• Status: Completed
• Phase: Phase 2
• Start date: December 7, 2018
• Est. completion date: February 26, 2021

Study information

• Verified date: May 2021
• Source: Recardio, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Dutogliptin in Combination with Filgrastim in Early Recovery Post-Myocardial Infarction

Description:

Dutogliptin 60 mg administered by twice daily subcutaneous (SC) injection for 14 days in combination with a fixed standard dose of filgrastim (10 µg/kg) administered SC daily for 5 days. This study will be conducted in adults with ST-elevation myocardial infarction (STEMI) with successful revascularization following percutaneous coronary intervention (PCI) and stent implantation.

Primary Objective

• To evaluate the safety and tolerability of dutogliptin in combination with filgrastim in subjects with STEMI compared with placebo

Secondary Objectives

• To assess preliminary efficacy of dutogliptin in combination with filgrastim in subjects with STEMI compared with placebo as determined by cardiac magnetic resonance imaging (cMRI)

• To determine the pharmacokinetics (PK) of dutogliptin in a subset of the study population

• To establish the pharmacodynamics (PD) of dutogliptin (plasma DPP4 activity) in a subset of the study population

Exploratory Objectives

• To examine the effects of dutogliptin in combination with filgrastim on:

• Change from baseline in plasma stromal cell-derived factor (SDF)-1a levels

• Change from baseline in plasma biomarkers, including N-terminal pro-b-type natriuretic peptide (NT-proBNP) and high sensitivity troponin

Recruitment information / eligibility

• Status: Completed
• Enrollment: 49
• Est. completion date: February 26, 2021
• Est. primary completion date: February 26, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

1. 1. Male or female born between 1933 and 2000.

2. Body weight <96 kg (212 lb).

3. Able to provide written informed consent, including signing and dating the informed consent form (ICF).

4. Diagnosis of STEMI (defined as new ST-segment elevation at the J point of at least 2 continuous leads of >2 mm [0.2 mV] in men or >1.5 mm [0.1 mV] in women in leads V2 and V3 OR >1 mm in any other contiguous precordial leads or the limb leads [for both men and women]) with PCI (bare metal or drug-eluting stent) and Thrombolysis in Myocardial Infarction flow grade 2 or 3 occurring >2 hours and <24 hours after symptom onset.

5. LVEF =45% obtained by cECHO performed within 36 hours post-stent placement.

6. Receiving standard medical therapy for post-MI treatment, according to local procedures and Principal Investigator discretion

7. Female subjects of childbearing potential must have a negative serum pregnancy test at Screening and an additional negative urine pregnancy test prior to the first dose of IMP unless regulated differently by national legislation.

8. Sexually active female subjects of childbearing potential (i.e., women who are not postmenopausal or who have not had a bilateral oophorectomy, hysterectomy, or tubal ligation) and all male subjects (who have not been surgically sterilized by vasectomy) must agree to use effective contraception during the study.

Exclusion criteria

1. Previous MI prior to Screening.

2. Complex peri/post-MI clinical course, including arrhythmias, cardiogenic shock, pulmonary edema requiring mechanical ventilation, or requirement for vasopressor medications.

3. Significant pre-existing cardiomyopathy with known LVEF =45% or moderate to severe mitral or aortic valvular disease.

4. Amyloidosis, hypertrophic obstructive cardiomyopathy, restrictive cardiomyopathy, or constrictive pericarditis.

5. Existing heart transplant.

6. Ventricular tachycardia or fibrillation not associated with an acute ischemic episode.

7. Uncontrolled hypertension (systolic >180 mmHg or diastolic >120 mmHg).

8. Treatment with any DPP4 inhibitors (e.g., alogliptin, linagliptin, vildagliptin, saxagliptin, sitagliptin) or G-CSF medication (e.g., filgrastim, lenograstim, pegfilgrastim, lipegfilgrastim) within 4 months prior to Randomization.

9. Contraindication to treatment with filgrastim, including known allergy to filgrastim or other G-CSF medication.

10. Anemia defined as hemoglobin <9 g/dL prior to Randomization.

11. Thrombocytosis (platelets >500 k/µL).

12. Known positive serology for hepatitis B, hepatitis C, or human immunodeficiency virus (HIV).

13. Alanine aminotransferase (ALT) concentrations >3 times the upper limit of normal (ULN) or bilirubin >2 x ULN prior to Randomization, according to local laboratory assessments.

14. History of cirrhosis and Child-Pugh score B or C.

15. Current fever greater than 101.4 °F (38.6 °C) or recent systemic infection within 2 weeks prior to Randomization.

16. Contraindication to cMRI procedure, including prior implantable cardioverter defibrillator placement, known reaction to gadolinium, claustrophobia, non-MRI-compatible, cochlear implant, morbid obesity, or presence of ferromagnetic material including shunts, shrapnel, penile prostheses, or blood vessel coil.

17. Pregnant, planning to become pregnant, or nursing female subjects.

18. Autoimmune disease requiring immunosuppressive therapy or chronic steroid treatment >5 mg/day prednisolone or equivalent.

19. Significant renal impairment defined as estimated glomerular filtration rate <45 mL/min/1.73 m2, using the Chronic Kidney Disease Epidemiology Collaboration equation.

20. Active neoplasm requiring surgery, chemotherapy, or radiation within the prior 12 months (subjects with a history of malignancy who have undergone curative resection or otherwise not requiring treatment for at least 12 months prior to Screening with no detectable recurrence are allowed).

21. Malignant hematological disease, i.e., chronic myeloid leukemia or myelodysplastic syndrome.

22. History of cerebrovascular accident or transient ischemic attack in the past 6 months.

23. History of pneumonia in the last 4 weeks.

24. History of any significant medical or psychiatric disorder that in the opinion of the investigator would make the subject unsuitable for participation in the study.

25. Treatment with an investigational drug within 30 days or 5 half-lives (whichever is longer) or treatment with an investigational biologic drug within 6 weeks prior to randomization.

26. Participation in another concurrent clinical trial involving a therapeutic intervention (participation in observational studies and/or registry studies is permitted).

27. Unable or unwilling to comply with the requirements of the study.

28. Subject and/or an immediate family member is an employee of the investigational site directly affiliated with this study, the sponsor or the contract research organization.

29. Considered by the investigator to be unsuitable to participate in the study for any other reason.

30. Persons who are in an institution as a result of an administrative or judicial order, or soldiers.

31. History of alcohol or drug abuse.

Related Conditions & MeSH terms

• Acute Myocardial Infarction
• Acute Myocardial Ischemia
• Infarction
• Ischemia
• Myocardial Infarction
• Myocardial Ischemia
• ST Elevation Myocardial Infarction
• STEMI - ST Elevation Myocardial Infarction

Intervention

Drug:
• Dutogliptin Tartrate
Active treatment
• Filgrastim Injectable Product
Active treatment
• Placebos
placebo control

Locations

Country	Name	City	State
Austria	Clinical department of Cardiology	Graz
Austria	Klinikum Klagenfurt am Wörthersee	Klagenfurt
Belgium	Algemeen Stedelijk Ziekenhuis Aalst	Aalst
Hungary	Military Hospital	Budapest
Hungary	Semmelweis Egyetem Városmajori Szív- és Érgyógyászati Klinika	Budapest
Hungary	Debreceni Egyetem Kardiológiai és Szívsebészeti Klinika	Debrecen
Hungary	Borsod-Abaúj-Zemplén Megyei Központi Kórház és Egyetemi Oktatókórház	Miskolc
Netherlands	Maasstad Ziekenhuis	Rotterdam
Poland	Nicolaus Copernicus University	Bydgoszcz
Poland	SPS Szpital Zachodni	Grodzisk Mazowiecki
Poland	Centralny Szpital Kliniczny Uniwersytetu Medycznego w Lodzi ul. Pomorska 251	Lódz
Poland	Samodzielny Publiczny Szpital Wojewódzki im. Papieza Jana Pawla II	Zamosc

Sponsors (1)

Lead Sponsor	Collaborator
Recardio, Inc.

Countries where clinical trial is conducted

Austria,  Belgium,  Hungary,  Netherlands,  Poland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety assessment of the number of Grade 3 and 4 treatment emergent AEs or serious AEs (SAEs) as assessed by CTCAE v4.0.AEs (SAEs) as assessed by CTCAE v4.0.	Assess the tolerability of a combination of dutogliptin and filgrastim	90 days
Secondary	Cardiovascular efficacy LVEF	Left ventricular ejection fraction (%) by MRI	90 days
Secondary	Cardiovascular efficacy LVESV	Left ventricular end systolic volume (mL) by MRI	90 days
Secondary	Cardiovascular efficacy LVEDV	Left ventricular end diastolic volume (mL) by MRI	90 days
Secondary	Cardiovascular tissue damage reduction	Infarct size (mm2)	90 days
Secondary	Cardiovascular LFM	Left ventricular mass (mm2)	90 days
Secondary	Cardiovascular motion	Regional wall motion (mm)	90 days
Secondary	Pharmacokinetics (PK)	Assess the systemic exposure (dutogliptin AUC) of s.c. administered dutogliptin	14 days
Secondary	Pharmacodynamics (PD)	Assess the PD effects (plasma DPP4 activity) of s.c. administered dutogliptin	14 days